OMB APPROVAL
	OMB Number: 3235-0145
	Expires: February 28, 2009
	Estimated average burden hours per response...10.4

 

 

Washington, D.C. 20549

Nymox Pharmaceutical Corporation

(Name of Issuer)

Common Shares

(Title of Class of Securities)

67076P102

(CUSIP Number)

December 31, 2008

(Date of Event Which Requires Filing of this Statement)

 

 

CUSIP No.		67076P102

**SEE ITEM 4.

CUSIP No.		67076P102

**SEE ITEM 4.

CUSIP No.		67076P102

**SEE ITEM 4.

CUSIP No.		67076P102

**SEE ITEM 4.

CUSIP No.		67076P102

**SEE ITEM 4.

CUSIP No.		67076P102

**SEE ITEM 4.

SCHEDULE 13G/A

This Amendment No. 2 to Schedule 13 G (the “Amendment”) is an amendment to the initial statement on Schedule 13G relating to common shares (the “Common Shares”) of Nymox Pharmaceutical Corporation (the “Issuer”) filed with the Securities and Exchange Commission (the “SEC”) on March 30, 2006 (the “Schedule 13G”).

This Amendment is being filed on behalf of Southpoint Capital Advisors LLC, a Delaware limited liability company (“Southpoint CA LLC”), Southpoint GP, LLC, a Delaware limited liability company (“Southpoint GP LLC”), Southpoint Capital Advisors LP, a Delaware limited partnership (“Southpoint Advisors”), Southpoint GP, LP, a Delaware limited partnership (“Southpoint GP”), Robert W. Butts and John S. Clark II. Southpoint CA LLC is the general partner of Southpoint Advisors. Southpoint GP LLC is the general partner of Southpoint GP. Southpoint GP is the general partner of Southpoint Fund LP, a Delaware limited partnership (the “Fund”), Southpoint Qualified Fund LP, a Delaware limited partnership (the “Qualified Fund”), and Southpoint Master Fund, LP, a Cayman Islands exempted limited partnership (the “Master Fund”). Southpoint Offshore Fund, Ltd., a Cayman Island exempted company (the “Offshore Fund”), is also a general partner of the Master Fund. This Schedule 13G relates to shares of Common Shares of the Issuer purchased by the Fund, the Qualified Fund and the Master Fund.

Item 1(a)		Name of Issuer.

Nymox Pharmaceutical Corporation

Item 1(b)		Address of Issuer’s Principal Executive Offices.

9900 Cavendish Blvd.
St. Lauren, QC, Canada H4M 2V2

Item 2(a)		Name of Person Filing.

	(1)		Southpoint Capital Advisors, LP
	(2)		Southpoint GP, LP
	(3)		Southpoint Capital Advisors, LLC
	(4)		Southpoint GP, LLC
	(5)		Robert W. Butts
	(6)		John S. Clark II

Item 2(b)		Address of Principal Business Office, or, if none, Residence.

(1)

For all Filers: 623 Fifth Avenue, Suite 2601 New York, NY 10022 (212) 692-6350

Item 2(c)		Citizenship or Place of Organization.

	(1)		Southpoint Capital Advisors LP is a Delaware limited partnership.
	(2)		Southpoint GP, LP is a Delaware limited partnership.
	(3)		Southpoint Capital Advisors LLC is a Delaware limited liability company.
	(4)		Southpoint GP, LLC is a Delaware limited liability company.
	(5)		Robert W. Butts is a U.S. citizen.
	(6)		John S. Clark II is a U.S. citizen.

Item 2(d)		Title of Class of Securities.

Common stock (the “Common Stock”).

Item 2(e)		CUSIP Number.

67076P102

Item 3		If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not Applicable

Item 4		Ownership.

Item 4 is hereby amended and restated as follows:

	(a)		Southpoint CA LLC, Southpoint GP LLC, Southpoint GP, Southpoint Advisors, Robert W. Butts and John S. Clark II may be deemed the beneficial owners of 2,932,780 shares of Common Shares.
	(b)		Southpoint CA LLC, Southpoint GP LLC, Southpoint GP, Southpoint Advisors, Robert W. Butts and John S. Clark II may be deemed the beneficial owners of 9.77% of the outstanding shares of Common Shares. This percentage was determined by dividing 2,932,780 by 30,021,626, the number of Common Shares issued and outstanding as of November 14, 2008, as reported in the Issuer’s report on form 6-K filed November 14, 2008.
	(c)		Southpoint CA LLC, Southpoint GP LLC, Southpoint GP, Southpoint Advisors, Robert W. Butts and John S. Clark II have the sole power to vote and dispose of the 2,932,780 shares of Common Shares beneficially owned.

Item 10		Certification.

By signing below each of the Reporting Persons certifies that, to the best of such person’s knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and were not held for

the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 17, 2009